Mitochondria, Metabolism and Heart Failure

joint with Diabetes and Metabolic Dysfunction

Organizer(s): Richard N. Kitsis, Gerald W. Dorn II and Rong Tian

Sponsored by Bayer HealthCare Pharmaceuticals and Takeda Pharmaceutical Company Limited. Supported by an educational donation provided by Amgen.

Summary of Meeting:

The most common causes of heart failure are coronary artery disease, high blood pressure and diabetes. Mitochondrial perturbations have been associated with heart failure itself, and with most of the other preceding risk factors. In some cases, mitochondrial dysfunction may play a causal role while in others mitochondria are a central target responsible for organ dysfunction. nderstanding mitochondrial pathophysiology and identifying ways to ameliorate mitochondrial dysfunction are critical to therapy for cardiovascular disease. Therefore, the overall objectives of this meeting are to: (1) Mechanistically connect the fundamental biology of metabolism and mitochondrial function with the pathogenesis of heart failure, a major cause of morbidity and mortality in the world; and (2) Increase basic understanding of metabolism and mitochondrial function using observations in cardiac muscle, a traditional platform for these studies. The ongoing convergence of the cardiac metabolism and mitochondrial biology fields provides a particularly cogent rationale for this meeting; moreover, large gaps of knowledge exist in this area such as the precise molecular signaling that connects metabolism and energy sensing with mitochondrial function, and the roles of basic mitochondrial processes (e.g., biogenesis, fission, fusion, mitophagy, maintenance of mitochondrial genome integrity) in metabolism and heart failure. These deficiencies in fundamentally important scientific knowledge and their clinical implications for a common and lethal disease confer exceptional significance on this conference. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Diabetes and Metabolic Dysfunction,” which will share a keynote address and three plenary sessions.

Scholarship Deadline: October 1 2014

Discounted Abstract Deadline: October 1 2014

Abstract Deadline: October 28 2014

Discounted Registration Deadline: November 25 2014

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

American Heart Association's Councils on Basic CV Sciences, and CV Disease in the Young

We gratefully acknowledge the generous grant for this conference provided by:

National Heart, Lung, and Blood Institute (NHLBI)
Grant No. 1R13HL126460-01
Funding for this conference was made possible (in part) by 1R13HL126460-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations